Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
Information source: Amgen
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Solid Tumours; Bone Metastasis
Intervention: Physician Survey (Other)
Phase: N/A
Status: Completed
Sponsored by: Amgen Official(s) and/or principal investigator(s): MD, Study Director, Affiliation: Amgen
Summary
Osteonecrosis of the Jaw (ONJ) is an adverse effect of antiresorptive therapy that is
well-recognized in patients with advanced cancer. Detailed information regarding this risk
is specified in the Summary of Product Characteristics (SPC). The statements in the SPC are
the most important mechanism for minimizing the risk for ONJ. The study objective is to
measure the knowledge of oncology practitioners prescribing XGEVA® regarding the content
pertaining to ONJ in the SPC after commercial availability.
Clinical Details
Official title: Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
Study design: Time Perspective: Cross-Sectional
Primary outcome: Proportion of participating oncology practitioners prescribing XGEVA® who are aware of the SPC statements pertaining to ONJ (each question pertaining to a SPC statement will be assessed seperately at the end of each survey round)
Detailed description:
This is a multiple cross-sectional survey study of practicing oncology practitioners
prescribing XGEVA in Europe from across but not limited to the 5 largest European countries
by population (including France, Germany, Italy, Spain and the U. K.) and 4 Nordic countries
(Denmark, Finland, Norway and Sweden). The survey will be conducted in two rounds. The two
survey rounds will be conducted 12 to 18 months and 24 to 30 months after XGEVA becomes
commercially available in the participating countries. The initial contact and screening of
potential participating oncology practitioners will continue until a total of 210 eligible
and consenting oncology practitioners complete the survey per round. For the 5 largest
European countries by population, it is intended that 30 oncology practitioners will be
surveyed per country per survey round. If this sample size cannot be achieved, oncology
practitioners from another country in that region will be surveyed to achieve a regional
sample size of 150 per survey round. Oncology practitioners from the Nordic countries will
be surveyed to achieve a regional sample size of 60 per survey round. For all countires, the
number of surveys collected in each country in the second survey round will, where possible,
equate to the number of surveys collected in each country in the first survey round.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Practicing oncology specialists who have treated at least 5 adult patients with bone
metastases from solid tumours in the last quarter. Must have prescribed XGEVA® within the
last 12 months. Must not have participated in a previous survey round
Locations and Contacts
Additional Information
AmgenTrials clinical trials website
Starting date: February 2013
Last updated: June 15, 2015
|